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Abstract
The optimal treatment for cervical cancer is still a controversial matter: in the last two decades a lot of different modalities combining
surgery, radiotherapy (RT) and chemotherapy (CHT) have been suggested and analysed in clinical trials. Nevertheless, analysis of treatment in
cancer patients should be directed not only to survival, but also to the cost of complications and quality of life. In June 1988, a French–Italian
co-operative group set up a glossary in which the complications of the treatment of cervical cancer are described and ranked. Nowadays,
this is the only international system based upon an accurate description of symptoms and signs of complications following multidisciplinary
treatment. The glossary was based on our previous experience in treating patients by surgery alone, RT or their combinations. Recently
multimodality treatment includes also CHT. The aim of the present study was to verify whether the glossary is still a useful clinical instrument
in outcome evaluation of cervical cancer treatment. Materials and methods: The analysis has been done on a retrospective consecutive series
of 579 patients affected by cervical cancer, treated in five Italian institutions. A minimum of 12 months follow up was required. All medical
records of the patients enrolled, were examined by two independent reviewers in order to classify the complications according to the glossary.
Results: Out of 579 patients 319 (55.1%) were free of complications and 260 (44.9%) experienced at least one complication. We found 436
complications. The distribution by Grade was: G1 58.9%, G2 27.5%, G3 13.5%. We had no fatal complication (G4). The glossary included
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all observed complications, except for pulmonary fibrosis. Conclusion: The glossary is still a useful instrument in evaluating the outcome of
cervical cancer treatment, whatever the therapy, and should be considered in quality of life assessment.
© 2003 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
The optimal treatment for cervical cancer is still a con-
troversial matter: in the last two decades a lot of differ-
ent modalities combining surgery, radiotherapy (RT) and
chemotherapy (CHT) have been suggested and analysed in
clinical trials. Nevertheless, analysis of treatment results in
cancer patients should be directed not only to survival rate,
but also to the cost of complications and quality of life [1].
Additional factors influencing the choice between different
treatment modalities at equal survival, include the age and
general condition of the patient, the need to preserve a func-
tional vagina and the complication rate for each treatment
[5].
In June 1988, a French–Italian co-operative group set up
a glossary in which the complications of the treatment of
cervical cancer are described and ranked (Table 1) [7–9].
Nowadays, this is the only international system based upon
an accurate description of symptoms and signs of compli-
cations following multidisciplinary treatments [4]. In recent
years, several authors have confirmed the reproducibility of
the glossary [1–6,12–15].
The aim of this study is to verify if the glossary is still
a useful clinical instrument in global outcome evaluation of
cervical cancer treatment [6].
Table 1
The glossary (summarised): complications by organ system and grade
Gastrointestinal
Rectum G1: a–d G2: a–d G3: a–c
Sigmoid colon G1: a–c G2: a–c G3: a–c
Small bowel G1: a–b G2: a–c G3: a–c
Stomach and duodenum G1: a–b G2: a–c G3
Non-specific abdominal
symptoms and/or signs
G1: a–b G2
Urinary
Bladder G1: a–f G2: a–d G3: a–d
Ureter G1: a–b G2: a–b G3: a–b
Vascular G1: a–d G2: a–d G3: a–d
Cutaneous G1: a–d G2: a–d G3: a–b
Uterus, vagina, vulva G1: a–f G2: a–d G3: a–c
Pelvic soft tissue G1: a–b G2: a–b G3: a–b
Bone G1 G2 G3
Peripheral nerves G1 G2 G3
Haemopoietic tissue G1 G2 G3
a–f indicate the type of complication (fistula, stress incontinence. . . ).
General grading system: G0: no complications, G1: mild complication,
G2: moderate complication, G3: severe complications, G4: death.
2. Materials and methods
The analysis was conducted on a retrospective consecutive
series of 579 patients treated for cervical cancer (FIGO stage
IA/IVB) in five Italian Institutions, from 1 January 1985 to
31 December 1999. A follow up time of 12 months, at least,
was required. The mean age of the patients was 50.7 years.
Every centre treated patients according to the treatment pro-
tocols of that particular Institution: the different protocols for
each stage varied from RT alone, to RT plus surgery, surgery
plus RT, surgery alone, CHT plus surgery, CHT plus RT,
CHT plus surgery plus RT or CHT alone (Tables 2 and 3).
All centres adopted the World Health Organisation
(WHO) histological classification for cervical cancer (83.5%
squamous, 13.2% adenocarcinoma, 3.2% adenosquamous,
0.2% clear cell) and FIGO classification for cervical cancer
staging (Table 4).
A specific clinical record sheet was adopted for surgery,
RT, CHT, pathology and follow up, and an extensive descrip-
tion of treatment complications was required. All medical
records of the patients enrolled were examined by two inde-
pendent reviewers in order to classify the complications ac-
cording to the glossary. The onset, persistence or resolution
of complications were registered at every follow up meeting.
Statistical analysis of survival was conducted with actu-
arial curves and Kaplan–Meier estimator; we analysed com-
plications using frequencies tablets and crosstablets.
3. Results
We analysed the 5-year clinical outcome: the recurrence
free survival at 5 years was similar to that reported in litera-
ture [6]. A figure showing actuarial survival by stage (Fig. 2)
is given.
Complications were classified as follows:
1) By NUMBER: we found 436 complications in 260 pa-
tients; 319/579 (55.1%) patients were complications free,
260/579 (44.9%) had one or more complication: 143
(27.4%) had one complication, 77 (13.3%) two compli-
cations, 26 (4.49%) three complications, ten (1.7%) four
complications, three (0.52%) five complications and only
one patient had six complications.
2) By DEGREE of SEVERITY: the great majority of com-
plications observed (58.9%) were mild (G1), 27.5% mod-
erate (G2) and 13.5% were severe complications (G3).
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Table 2
Treatments
RT RT+surg Surg+RT Surg CHT+surg CHT+RT CHT+surg+RT CHT
2.7% 4.2% 30.4% 24.2% 15.2% 9.7% 12.9% 0.5%
Table 3
Treatments for stage
IB (%) IIA (%) IIB (%) III (%) IV (%)
RT 1.3 4.2 5.7 3.7 15.4
RT+surg 3.5 5.2 11.3 / /
Surg+RT 34 36.5 13.2 3.7 7.7
Surg 32.7 11.5 3.8 3.7 /
CHT+surg 16 13.5 17 11.1 7.7
CHT+RT 4 8.3 24.5 51.9 38.5
CHT+surg+RT 8.5 20.8 24.5 25.9 7.7
CHT / / / / 23.1
100 100 100 100 100
We had no fatal complication (G4). Almost 2/3 of com-
plications were mild (G1).
3) By ORGAN SYSTEM and DEGREE (tab. *): G1
reached 59.1% in gastrointestinal (G.I.) and 43.3% in
urological sites, 63.6% in pelvic soft tissue, 69% in the
skin, 70% in genital sites and 76.9% in vascular sites.
28% of the G.I., 34% of the urinary, 36.4% of the pelvic
soft tissues, 27.6% of the cutaneous and 38.9% of the
nervous complications were G2. G3 occurred in 12.9%
of the G.I., 22.7% of the urinary and 11.1% of the ner-
vous complications. We observed two pulmonary G3
complications too (pulmonary fibrosis), not described in
the glossary. No complications were found in this series
involving bone.
4) The urinary tract is the dominant site of complications
of any grade and, particularly, 1/3 G2 and half G3 com-
plications are located in this system. The second most
frequent site of complications is G.I. Urinary and G.I.
systems account, together, for 45.2% of all G1, 61.7%
of all G2 and 74.6% of all G3 complications (Table 5).
5) By TIME of ONSET and DEGREE: the median delay
between the end of the treatment and the onset of mild
complications (G1) was 8 months, 12 months for mod-
erate (G2) and 10 months for severe (G3). We observed
that 95% of complications appeared within 36 months,
but 18 G1, 5 G2 and 2 G3 appeared between 3 and 5
years after the end of treatment and 33 complications
more later than 5 years (G1:16, G2:14, G3:3) (Fig. 1).
6) By TIME of ONSET and ORGAN: G.I., urinary and
vascular complications appeared in almost all the inter-
vals of 6 months, the maximum number of events being
concentrated at 6/12 months from the end of the treat-
Table 4
Distribution for stage
FIGO stage IA IB IIA IIB IIIA IIIB IVA IVB
Number of patients (%) 11 (1.9%) 378 (65.3%) 97 (16.8%) 53 (9.2%) 10 (1.7%) 17 (2.9%) 10 (1.7%) 3 (0.5%)
Table 5
Total number of complications by organ site and grade
G1 G2 G3 Total
G.I. 55 26 12 93
Urinary 61 48 32 141
Vascular 60 13 5 78
Cutaneous 20 8 1 29
Uterus–vagina–vulva 40 13 4 57
Pelvic soft tissue 7 4 / 11
Peripheral nerves 9 7 2 18
Bone / / / /
Haemopoietic tissue 5 1 1 7
Total 257 120 59 436
ment. An inferior number of complications tend to ap-
pear between 18 and 34 months in G.I., urinary, vascular
and uterus–vagina–vulva. As well we observed onset of
10 G.I., seven uterus–vagina–vulva, nine urinary and six
vascular complications after 60 months from the end of
the treatment (Fig. 1).
7) By ORGAN SITES: out of 93 complications concerning
G.I. sites, 42 involved the rectum (45.2%), 21 (22.6%)
were a specific abdominal signs or symptoms, and 18
(19.4%) involved colon. 103/132 urinary complications
involved bladder and urethra (only 9.9% G3), 29/132
complications involved ureters. Out of 18 complications
concerning nervous system, 16 (88.9%) involved periph-
eral nerves and only two (11.1%) G2 involved CNS.
8) By TREATMENT: the major complication rate by
treatment modality was found in patients treated with
Fig. 1.
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Fig. 2. Disease-free survival by FIGO stage.
RT alone (19/15-1.27), followed by RT plus surgery
(22/24-0.91) and neoadjuvant CHT plus surgery plus
RT (66/73-0.9). The less complicated treatment modal-
ity was CHT plus RT (16/55-0.29), but not by con-
current approach, and neoadjuvant CHT plus surgery
(30/86-0.35). The major incidence of urinary compli-
cations was found in patients treated by surgery alone,
almost 45% of all complications onset in this treat-
ment group, followed by surgery plus RT and CHT
plus surgery plus RT (33–35%). The major incidence
of G.I. complications was found in chemo-radiotherapy
(44%) and in RT alone subgroup (37%). The ma-
jor incidence of genital and pelvis complications was
found in RT (32%) and RT plus surgery subgroup
(27%). Pulmonary complications were found in patients
CHT-treated.
4. Discussion and conclusions
In modern oncology, survival rate is the primary endpoint
in treatment evaluation, but quality of life and analysis of
treatment complications are equally of crucial importance.
The use of a common instrument for objective observation
criteria and commonly accepted definitions in the classifi-
cation of complications is required for a correct analysis of
each treatment modality.
In this series, we found complications in 44.9% of patients
analysed: this value is at the upper limit of the range re-
ported in literature (22–50%) [1–6,12–15], but we reported
all complications, even if mild or showing for a short time.
As reported in the literature, the most affected organ
systems by complications are urinary and G.I., followed
by vascular and uterus–vagina–vulva. In this subgroup,
the most affected organs were bladder and rectum, ac-
cording to the major damage of locoregional treatment
[1,6,10].
The glossary allows classification and quantification of
events sometimes subject to different interpretation by dif-
ferent researchers: in our series, two independent review-
ers had complete agreement in classifying complications by
analysing medical records where complications were exten-
sively described. The only complication not codified by the
glossary was pulmonary fibrosis in two bleomicin-treated
patients. On the other hand, we had no complication regard-
ing bone system.
Furthermore, the glossary is suitable in following the
persistence, worsening or resolution (spontaneous or af-
ter treatment) of the complications, allowing to evaluate
the evolution of the complication in relation to time from
treatment [1].
Pedersen wrote that is necessary to avoid underestima-
tion of morbidity, with any classification system, to register
each symptom, its time of appearance and its grade [11].
This is necessary to allow reporting of the real risk of or-
gan damage, rescoring of complication grade, separation of
early and late morbidity and reporting of actuarial estimates
[1,11]. The French–Italian glossary answers to all these re-
quirements. This instrument suggests a common language
for the outcome evaluation of cervical cancer treatment not
only in terms of survival and recurrence, but of observed
toxicity too [1].
The glossary is still a useful instrument in evaluating the
outcome of cervical cancer treatment, independently from
therapy, and it should be considered in quality of life assess-
ment.
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